Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PITA 3: Peanut Oral Induction Tolerance in Allergic Teenagers
NCT02046083Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Jul 2013
- Primary completion
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of arachidonic acid in peanut allergy (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Percentage of patients which tolerate the cumulative dose of 2 grams of peanut at 24 weeks. Started Jul 2013; status: completed.
02
Drugs
arachidonic acid
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT02046083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046083.